Cell

Virtuosi® Becomes an IACET Accredited Provider

Retrieved on: 
Tuesday, April 9, 2024
Microbiology, Organization, Accreditation, VR, Education, Aseptic processing, Senior, Quality, Continuing education, Cell, ANSI, Virtual reality, Nursing

ATLANTA, April 9, 2024 /PRNewswire/ --The International Accreditors for Continuing Education and Training (IACET) has awarded Virtuosi the prestigious Accredited Provider accreditation. IACET Accredited Providers are the only organizations approved to offer IACET Continuing Education Units (CEUs).

Key Points: 
  • ATLANTA, April 9, 2024 /PRNewswire/ --The International Accreditors for Continuing Education and Training (IACET) has awarded Virtuosi the prestigious Accredited Provider accreditation.
  • IACET Accredited Providers are the only organizations approved to offer IACET Continuing Education Units (CEUs).
  • "We are pleased to recognize and celebrate the achievement of Virtuosi powered by Quality Executive Partners as an Accredited Provider," stated Randy Bowman, President & CEO of IACET.
  • Virtuosi is now linked to the IACET website and is recognized as offering the highest quality continuing education and training programs.

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

Retrieved on: 
Tuesday, April 9, 2024
CHIPS, Obesity, Biotechnology, Growth, Cell, Diabetes, Equivalence relation, Artificial intelligence, OSM, Acquisition, Science, Messenger, Investment, Semiconductor, European Chips Act, JGC Holdings Corporation, Inflation, Data, Engineering, EPC, Video game

STUTTGART, Germany, April 9, 2024 /PRNewswire/ -- Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, showed strong growth trajectory in Europe and the USA in its fiscal year 2023.

Key Points: 
  • STUTTGART, Germany, April 9, 2024 /PRNewswire/ -- Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, showed strong growth trajectory in Europe and the USA in its fiscal year 2023.
  • We benefit in Europe and the USA from extensive investments in high-tech facilities," says Exyte CEO Dr. Wolfgang Büchele.
  • The share of Asia is declining, while order intake and sales are increasing significantly in Europe and the USA.
  • In both Europe and the USA, we are expanding our organization to execute our clients' planned mega-projects," says Exyte board member Mark Garvey.

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

Retrieved on: 
Tuesday, April 9, 2024
CHIPS, Obesity, Biotechnology, Growth, Cell, Diabetes, Equivalence relation, Artificial intelligence, OSM, Acquisition, Science, Messenger, Investment, Semiconductor, European Chips Act, JGC Holdings Corporation, Inflation, Data, Engineering, EPC, Video game

STUTTGART, Germany, April 9, 2024 /PRNewswire/ -- Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, showed strong growth trajectory in Europe and the USA in its fiscal year 2023.

Key Points: 
  • STUTTGART, Germany, April 9, 2024 /PRNewswire/ -- Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, showed strong growth trajectory in Europe and the USA in its fiscal year 2023.
  • We benefit in Europe and the USA from extensive investments in high-tech facilities," says Exyte CEO Dr. Wolfgang Büchele.
  • The share of Asia is declining, while order intake and sales are increasing significantly in Europe and the USA.
  • In both Europe and the USA, we are expanding our organization to execute our clients' planned mega-projects," says Exyte board member Mark Garvey.

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Penetrance, HER2, Mutagenesis, EGFR, Cell, Patient, CNS, Cancer, ENU, Human, Senior, TRK, AACR, Crizotinib, ROS1, Drug discovery, Vaccine

CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data for its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520). The two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5 – 10 in San Diego. The posters will also be available on the Nuvalent website at www.nuvalent.com following the presentations.

Key Points: 
  • The two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5 – 10 in San Diego.
  • The posters will also be available on the Nuvalent website at www.nuvalent.com following the presentations.
  • "Today's presentations continue to reinforce the differentiated profiles of our drug candidates," said Henry Pelish, Ph.D., Senior Vice President of Drug Discovery at Nuvalent.
  • These mutagenesis screens provide additional preclinical support for zidesamtinib's potential to drive deep and durable responses for patients with ROS1-driven cancers.

Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Research, BCL9, MDSC, Survival, Patient, Wisdom, SVP, Neoplasm, The central science, Cancer, Macrophage, AP-1, IND, AACR, TAM, Phenotype, Therapy, Breast cancer, Poster, Cell, AP-1 transcription factor, TNBC, Metastasis, Vaccine

TARRYTOWN, N.Y., April 8, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced the presentation of new data on its clinical and pipeline programs during three poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, CA.

Key Points: 
  • We look forward to ST316 and ST101 continuing to advance through clinical development and moving our AP-1 program into IND-enabling studies."
  • Sapience scientists will present non-clinical immune-oncology results from both of its clinical programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ.
  • In nonclinical studies, Sapience evaluated the ability of ST316 to enhance anti-tumor immune responses in combination with anti-PD-1 and anti-TIGIT therapies.
  • JunAP demonstrates potent anti-tumor activity in vivo in mouse triple negative breast cancer and melanoma tumor models.

IDTechEx Release New Global Advanced Li-ion Battery Technologies Market Report

Retrieved on: 
Friday, April 5, 2024
Research, Lithium, Players, Content, Silicon, Table of contents, NMC, Cell, BMS, Electrolyte, Electric battery

BOSTON, April 5, 2024 /PRNewswire/ -- IDTechEx Research, a trusted provider of independent market intelligence, announces the availability of a new report, " Advanced Li-ion Battery Technologies 2024-2034: Technologies, Players, Forecasts ."

Key Points: 
  • BOSTON, April 5, 2024 /PRNewswire/ -- IDTechEx Research, a trusted provider of independent market intelligence, announces the availability of a new report, " Advanced Li-ion Battery Technologies 2024-2034: Technologies, Players, Forecasts ."
  • The development of advanced and next-generation Li-ion technologies will be critical to a number of sectors, as well as for battery companies aiming to succeed or maintain their place in the market.
  • The global market for Li-ion battery cells alone is forecast to reach US$380 billion by 2034, driven primarily by demand for battery electric cars and vehicles.
  • This battery technologies market report provides the following information:
    Introduction to Li-ion battery technologies.

IDTechEx Release New Global Advanced Li-ion Battery Technologies Market Report

Retrieved on: 
Friday, April 5, 2024
Research, Lithium, Players, Content, Silicon, Table of contents, NMC, Cell, BMS, Electrolyte, Electric battery

BOSTON, April 5, 2024 /PRNewswire/ -- IDTechEx Research, a trusted provider of independent market intelligence, announces the availability of a new report, " Advanced Li-ion Battery Technologies 2024-2034: Technologies, Players, Forecasts ."

Key Points: 
  • BOSTON, April 5, 2024 /PRNewswire/ -- IDTechEx Research, a trusted provider of independent market intelligence, announces the availability of a new report, " Advanced Li-ion Battery Technologies 2024-2034: Technologies, Players, Forecasts ."
  • The development of advanced and next-generation Li-ion technologies will be critical to a number of sectors, as well as for battery companies aiming to succeed or maintain their place in the market.
  • The global market for Li-ion battery cells alone is forecast to reach US$380 billion by 2034, driven primarily by demand for battery electric cars and vehicles.
  • This battery technologies market report provides the following information:
    Introduction to Li-ion battery technologies.

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Civil service commission, Salt, Diagnosis, Absorption, Microvillous inclusion disease, DSM-IV codes, Nutrient, Cell, Patient, Committee, Weight loss, Knowledge, Regulation, Food, EMA, IRIS, Noetics, Parenteral nutrition, Diarrhea, European, Malnutrition, COMP, Dehydration, Water, Safety, European Commission, Liver, Medicine, Pharmaceutical industry

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Key Points: 


Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Orphan designation: idebenone Treatment of Leber's hereditary optic neuropathy, 16/02/2007 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Leber's hereditary optic neuropathy, Prevalence, Cell, Patient, Committee, Knowledge, Seriousness, Mitochondrion, Regulation, EMA, IRIS, Adolescence, LHON, European, COMP, Oxygen, Safety, European Commission, Marketing, Visual impairment, Medicine, Pharmaceutical industry

Orphan designation: idebenone Treatment of Leber's hereditary optic neuropathy, 16/02/2007 Positive

Key Points: 


Orphan designation: idebenone Treatment of Leber's hereditary optic neuropathy, 16/02/2007 Positive

Orphan designation: imatinib Treatment of pulmonary arterial hypertension, 21/06/2021 Positive

Retrieved on: 
Tuesday, April 9, 2024
Community, Diagnosis, Civil service commission, Enzyme, Prevalence, Cell, Disease, Patient, Committee, Cancer, EMA, IRIS, Imatinib, Orthostatic hypertension, Agency, European, COMP, European Commission, MDC, PAH, Marketing, FGK, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of pulmonary arterial hypertension (PAH) in the European Union on 21 June 2021.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: